These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 18312362

  • 1. Fifteen years of population based experience in Finland with a plasma-derived monoclonal purified factor VIII concentrate.
    Mäkipernaa A, von Bonsdorff L.
    Haemophilia; 2008 May; 14(3):612-4. PubMed ID: 18312362
    [No Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP, Posthouwer D, Fischer K, van den Berg HM.
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety evaluation of sucrose-formulated recombinant factor VIII for Taiwanese patients with haemophilia A.
    Young JH, Liu HC, Hsueh EJ, Huang ML, Peng CT, Chen RL, Maas-Enriquez M, Achilles K.
    Haemophilia; 2009 Jul; 15(4):968-70. PubMed ID: 19473407
    [No Abstract] [Full Text] [Related]

  • 4. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A.
    Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, Hanley J, Paediatric Working Party of the United Kingdom Haemophilia Doctors' Organisation.
    Br J Haematol; 2010 May; 149(4):498-507. PubMed ID: 20230411
    [Abstract] [Full Text] [Related]

  • 5. Maintenance of treatment logs by haemophilia patients.
    du Treil S, Rice J, Leissinger CA.
    Haemophilia; 2010 May; 16(3):545-7. PubMed ID: 20050930
    [No Abstract] [Full Text] [Related]

  • 6. Factor VIII: maximal benefit?
    Nour-Eldin F.
    Eur J Med; 1992 Apr; 1(1):55-7. PubMed ID: 1341979
    [No Abstract] [Full Text] [Related]

  • 7. New treatment for hemophilia.
    FDA Consum; 2003 Apr; 37(6):5. PubMed ID: 14983810
    [No Abstract] [Full Text] [Related]

  • 8. Acquired hemophilia: a clinical experience.
    Mirza MA, Khimani F, Rogers J.
    W V Med J; 2010 Apr; 106(7):32-5. PubMed ID: 21932489
    [No Abstract] [Full Text] [Related]

  • 9. Viral safety issues: plasma-derived factor VIII.
    Berntorp E.
    Ann Hematol; 1994 Apr; 68 Suppl 3():S35-6. PubMed ID: 8180256
    [No Abstract] [Full Text] [Related]

  • 10. Postpartum acquired factor VIII inhibitors.
    Franchini M.
    Am J Hematol; 2006 Oct; 81(10):768-73. PubMed ID: 16868941
    [Abstract] [Full Text] [Related]

  • 11. Hemophilia care in the 21st century.
    Kempton CL, Escobar MA, Roberts HR.
    Clin Adv Hematol Oncol; 2004 Nov; 2(11):733-40. PubMed ID: 16170890
    [No Abstract] [Full Text] [Related]

  • 12. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP, Rice KM, Savidge GF.
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract] [Full Text] [Related]

  • 13. In vivo recovery and safety of human factor VIII product AAFACT in patients with haemophilia A.
    Vossebeld PJ, Tissing MH, Van Den Berg HM, Leebeek FW, De Goede-Bolder A, NovAkovA IR, Gerrits WB, Peters M, Koopman MM, Faber A, Hiemstra H, Grob P, Strengers PF.
    Haemophilia; 2003 Mar; 9(2):157-63. PubMed ID: 12614366
    [Abstract] [Full Text] [Related]

  • 14. Haemate P von Willebrand factor/factor VIII concentrate: 25 years of clinical experience.
    Schramm W.
    Haemophilia; 2008 Nov; 14 Suppl 5():3-10. PubMed ID: 18786006
    [Abstract] [Full Text] [Related]

  • 15. Concentrate safety and efficacy.
    Kasper CK.
    Haemophilia; 2002 May; 8(3):161-5. PubMed ID: 12010404
    [Abstract] [Full Text] [Related]

  • 16. [Treatment with plasma concentrates in hemophilia A. State Security and Health Planning Office. Expert Panel].
    Sangre (Barc); 1994 Apr; 39(2):157-61. PubMed ID: 8059299
    [No Abstract] [Full Text] [Related]

  • 17. Including the life-time cumulative number of joint bleeds in the definition of primary prophylaxis.
    den Uijl IE, Fischer K.
    Thromb Haemost; 2008 May; 99(5):965; author reply 966-8. PubMed ID: 18449430
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
    Gringeri A.
    Haemophilia; 2007 Dec; 13 Suppl 5():73-7. PubMed ID: 18078402
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.